title: The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia.
abstract: B-cell lymphoma 2 (BCL2)-type proteins are key regulators of the intrinsic or mitochondrial pathway for apoptosis. Since escape from apoptosis is one the main 'hallmarks of cancer', BCL2 inhibitors have emerged as promising therapeutic agents for diverse lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). Multiple clinical trials have shown efficacy of these agents in patients with relapsed/refractory disease with a favorable toxicity profile. Moreover, some clinical trials indicate that combination with monoclonal antibodies and other novel agents may enhance their effect.
authors.affiliation: Department of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: Valentín
authors.initials: V
authors.lastname: Ortíz-Maldonado
authors.affiliation: Department of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Mozas
authors.affiliation: Department of Hematology, Hospital Clínic, IDIBAPS, Calle Villarroel 170, 08036 Barcelona, Spain.
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
keywords: B-cell lymphoma 2; BH3-mimetics; chronic lymphocytic leukemia